Business
Premier Biomedical Files Provisional Patent Application on Second Drug to Treat Fibromyalgia, Neuropathic Pain, MS Symptoms, and Alcohol and Chemical Addiction
Premier Biomedical Files Provisional Patent Application on Second Drug to Treat Fibromyalgia, Neuropathic Pain, MS Symptoms, and Alcohol and Chemical Addiction.
About this update from Premier Biomedical Inc
[{"type":"text","content":"\n \n Premier Biomedical, Inc.(OTCQB:\"BIEI\") \n a biotech research company focused on discovering, developing, and \n commercializing medical treatments for a wide range of diseases in \n humans, including innovative therapies for breast cancer, as well as for \n neurofibromatosis, atherosclerosis and muscular dystrophy, announced the \n filing of a provisional patent on a second drug to treat fibromyalgia, \n neuropathic pain, MS symptoms, and alcohol and chemical addiction. This \n new drug is in addition to Premier’s existing Feldetrex® drug, to \n compete in this segment of the health care market representing an \n opportunity of $16B annually.\n \n \n William A. Hartman, President and CEO of Premier Biomedical stated, “We \n are continuing to advance our technology to improve and expand our \n healthcare products to help relieve the pain and suffering of patients \n afflicted with these diseases and conditions, not only here in the U.S., \n but also in Brazil, Asia and Europe through pending and future joint \n ventures.”\n \n \n Contact William Hartman at (724) 633-7033, [email protected].\n \n \n About Premier Biomedical, Inc.\n \n \n Premier \n Biomedical, Inc. (OTCQB:BIEI) \n is a research-based company that intends to discover and develop medical \n treatments for a wide range of diseases in humans. Premier has obtained, \n via license agreements, the technology behind multiple provisional \n patents in the United States and a PCT Europe National Patent. Founded \n in 2010, Premier has partnered with the Department of Defense with \n Center of Expertise at the William Beaumont Army Medical Center. The \n company's R&D efforts are centered in El Paso, TX. The Company is a \n fully-reporting issuer whose common stock trades on the OTCQB \n marketplace maintained by OTC Markets Group, Inc. under the ticker \n symbol \"BIEI\".\n \n \n For more information, visit our website http://www.premierbiomedical.com/.\n \n \n Safe Harbor Notice\n \n \n Certain statements contained herein are “forward-looking statements” (as \n defined in the Private Securities Litigation Reform Act of 1995). \n Premier Biomedical, Inc. cautions that statements, and assumptions made \n in this news release constitute forward-looking statements and makes no \n guarantee of future performance. Forward-loo...